Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78278343 in Advanced Prostate Cancer
NCT04898634Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of pasritamig in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Adverse Events by Severity and 1 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
pasritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04898634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898634.